Want to see GB:CLBX full AI Analyst Report?
ANGLE plc (CLBX) AI Stock Analysis
ANGLE plc
(LSE:CLBX)
The stock scores poorly due to critical financial weaknesses including unsustainable losses and cash burn, compounded by a strong technical downtrend. Negative valuation and funding risks from the earnings call further weigh on the outlook, despite progress in strategic partnerships.
ANGLE plc (CLBX) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 6.82M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.99M
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 1.09
- Revenue Growth
- -56.10%
- EPS Growth
- 41.10%
- Country
- UK
- Employees
- 114
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
ANGLE plc Business Overview & Revenue Model
Company Description
CelLBxHealth plc is a medical diagnostics firm specializing in the creation of cancer detection solutions, with operations spanning the United Kingdom, broader Europe, North America, and other global markets. A flagship offering is the Parsortix PC1...
How the Company Makes Money
ANGLE generates revenue primarily through the sale of its Parsortix systems and related consumables. The company also earns income from service contracts and collaborations with research institutions and pharmaceutical companies that utilize its tech...
ANGLE plc Earnings Call Summary
ANGLE's earnings call presented a balanced outlook with significant achievements in pharma collaborations and technology development, but also faced challenges from adverse market conditions affecting revenue and the need for additional funding.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the ANGLE 2025 Interim Results Call, CEO Andrew Newland provided comprehensive guidance on the company's financial and operational progress for the first half of the fiscal year. Despite facing adverse market conditions that pressured revenue, with pharma revenue down and product revenue flat compared to the prior year, ANGLE has made significant strides in commercialization and development. Key achievements include the completion of three major pharma projects with Eisai and AstraZeneca, the development of the DNA dual analysis using Illumina's NGS assay, and the commencement of a collaboration with Myriad Genetics for large-scale commercialization of the Parsortix system. The company has maintained tight cost control, reducing operating expenditure by 12%, and holds a cash position of GBP 6.6 million, with a runway extending into Q1 2026. Despite the challenging environment, ANGLE anticipates further developments with multiple large pharma and med tech companies and is actively pursuing additional funding sources to ensure continued growth and innovation in its cancer diagnostic solutions.
ANGLE plc Financial Statement Overview
Summary
Severe financial challenges with steep losses (net margin -497%), declining revenue (-4.3% TTM), and negative cash flows. Low debt provides stability, but negative ROE (-104.7%) indicates significant equity erosion.
Income Statement
10Very NegativeBalance Sheet
40NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.62M | 2.86M | 2.19M | 1.04M | 1.01M | 762.00K |
| Gross Profit | 1.63M | 1.78M | -408.00K | 613.00K | 711.00K | 597.00K |
| EBITDA | -15.60M | -13.02M | -19.48M | -22.06M | -15.74M | -12.29M |
| Net Income | -15.78M | -14.22M | -20.13M | -21.69M | -15.01M | -11.61M |
Balance Sheet | ||||||
| Total Assets | 18.08M | 25.46M | 31.18M | 49.87M | 47.31M | 39.05M |
| Cash, Cash Equivalents and Short-Term Investments | 5.27M | 10.43M | 16.22M | 31.90M | 31.84M | 28.62M |
| Total Debt | 3.67M | 4.21M | 4.55M | 5.00M | 2.34M | 1.36M |
| Total Liabilities | 6.39M | 7.02M | 8.24M | 9.80M | 6.99M | 4.71M |
| Stockholders Equity | 11.69M | 18.44M | 22.94M | 40.06M | 40.33M | 34.34M |
Cash Flow | ||||||
| Free Cash Flow | -11.62M | -13.89M | -15.12M | -17.94M | -15.80M | -8.35M |
| Operating Cash Flow | -11.25M | -13.45M | -14.46M | -16.05M | -14.01M | -7.85M |
| Investing Cash Flow | -491.50K | -48.00K | -203.00K | -1.75M | 14.77M | -1.97M |
| Financing Cash Flow | -2.05M | 7.67M | -1.13M | 18.10M | 18.99M | 18.14M |
ANGLE plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CLBX, the sentiment is Negative. The current price of 0.56 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.92, and below the 200-day MA of 1.15, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 19.85 is Positive, neither overbought nor oversold. The STOCH value of 26.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CLBX.
ANGLE plc Peers Comparison
Overall Rating
GB:DXRX59Neutral
GB:GDR49Neutral
GB:ABDX46Neutral
GB:VRCI44Neutral- GB:CLBX40Underperform
GB:PRM37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:DXRX | 59Neutral | GBP 172.63M | -635.94 | -0.68% | ― | 20.14% | 82.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:GDR | 49Neutral | GBP 15.65M | -0.89 | -1044.57% | ― | 65.60% | 74.84% |
| GB:ABDX | 46Neutral | GBP 22.75M | -16.36 | -34.31% | ― | 30.42% | 43.16% |
| GB:VRCI | 44Neutral | GBP 15.32M | -0.60 | -127.57% | ― | 77.87% | 84.36% |
| GB:CLBX | 40Underperform | GBP 6.82M | -0.49 | -104.73% | ― | -56.10% | 41.10% |
| GB:PRM | 37Underperform | GBP 5.10M | -1.99 | 23.85% | ― | -16.72% | 36.28% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:CLBX | ANGLE plc | 0.60 | -1.50 | -71.43% | |
| GB:GDR | Genedrive plc | 0.97 | -0.04 | -3.75% | |
| GB:PRM | Proteome Sciences | 1.46 | -0.19 | -11.55% | |
| GB:DXRX | Diaceutics Plc | 202.50 | 40.00 | 24.62% | |
| GB:VRCI | Verici Dx Plc | 0.23 | -0.40 | -63.20% | |
| GB:ABDX | Abingdon Health PLC | 9.00 | 2.75 | 44.00% |
ANGLE plc Corporate Events
CelLBxHealth Tightens Costs and Reshapes Strategy as 2025 Revenues Miss Target
NegativeCelLBxHealth reported preliminary unaudited 2025 revenues of about £1.4 million, slightly below expectations after roughly £0.2 million of anticipated sales slipped into the first quarter of 2026, while year-end cash stood at £7.3 mill...
CelLBxHealth refreshes board and appoints new CEO to drive CTC growth strategy
PositiveCelLBxHealth plc has strengthened its board with the immediate appointment of Peter Collins as chief executive officer and Klaas de Boer, Kim Oreskovic and Benjamin Hart as non-executive directors, while non-executive director Joseph Eid will step do...
CelLBxHealth Executives and ESOT Boost Holdings After Oversubscribed Placing
PositiveCelLBxHealth plc has disclosed significant share purchases by its top executives following last month’s oversubscribed placing, with Executive Chairman Jan Groen and CEO Peter Collins each acquiring 5 million shares and Finance Director Sin...
CelLBxHealth Announces Board Changes and Share Capital Reorganization
PositiveCelLBxHealth plc announced that all resolutions were approved at their General Meeting, paving the way for significant changes, including the transition of Peter Collins from Interim CEO to CEO and the anticipated appointment of new board members in...
CelLBxHealth Secures Additional Investment from Acacia Funds
PositiveCelLBxHealth plc announced an additional subscription by Conifer Management, LLC, on behalf of the Acacia funds, for 40,891,541 new ordinary shares, raising approximately £0.4 million. This additional subscription, part of a larger fundraising e...
CelLBxHealth plc Successfully Closes Retail Offer, Raising £0.96 Million
PositiveCelLBxHealth plc has successfully closed its Retail Offer, raising approximately £0.96 million, with plans to issue 95,869,449 shares at 1.0 pence each, contingent upon the passing of resolutions at an upcoming General Meeting. The company aims...
CelLBxHealth Announces Update on Fundraising Shares Admission
PositiveCelLBxHealth plc announced an update regarding the admission of fundraising shares following an oversubscribed placing. The first tranche of 9,090,000 shares is expected to be admitted on December 16, 2025, with a second tranche of up to 770,910,000...
CelLBxHealth plc Completes Oversubscribed Fundraising to Enhance Market Position
PositiveCelLBxHealth plc has successfully concluded an oversubscribed placing and subscription, raising approximately £6.8 million through the issuance of new shares at a discounted price. This fundraising effort is aimed at expanding the company’...
CelLBxHealth Launches Retail Share Offer to Boost Funding
NeutralCelLBxHealth plc, a company focusing on healthcare solutions, has announced a retail offer of new ordinary shares at a discounted issue price of 1.0 pence per share. This offer is part of a larger fundraising initiative that includes a conditional pl...
CelLBxHealth Announces £6.8 Million Fundraising to Drive Commercial Strategy
PositiveCelLBxHealth plc has announced a proposed fundraising of £6.8 million through a placing, subscription, and retail offer to support its revised business strategy. The company aims to transition from a research-focused organization to a commercial...
CelLBxHealth Partners with QIAGEN to Enhance CTC-Based Research
PositiveCelLBxHealth plc has announced a collaboration and co-marketing agreement with QIAGEN Manchester Ltd. to advance CTC-based research. This partnership will combine CelLBxHealth’s Parsortix platform with QIAGEN’s molecular technologies to e...
CelLBxHealth plc Announces £6 Million Fundraising Initiative
NeutralCelLBxHealth plc has announced its intention to raise approximately £6 million to extend its cash runway into early 2026. The company is in discussions with shareholders and plans to make an offer to retail investors alongside an institutional p...
CelLBxHealth Unveils Promising Study on CTC Integration with Roche’s Diagnostic Platform
PositiveCelLBxHealth plc has announced a successful proof-of-concept study demonstrating the compatibility of its Parsortix platform with Roche Tissue Diagnostics’ BenchMark ULTRA automated staining system. This study, presented at the World ADC Confer...
CelLBxHealth’s Parsortix® Platform Recognized as Leading Technology in CTC Analysis
PositiveCelLBxHealth plc announced a major international expert consensus highlighting the clinical relevance of circulating tumor cell (CTC) analysis in cancer management, with the Parsortix® platform identified as a leading next-generation technology....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 07, 2025